Table 2.
Ongoing phase 2/3 trial with PD-1 inhibitor combined with chemotherapy in first-line treatment of esophageal carcinoma.
| Trial | Phase | Status | Drug | Tumor | Treatment |
|---|---|---|---|---|---|
| KEYNOTE-590—China Extension Study | 3 | Recruiting | Pembrolizumab+Cisplatin+5-FU/Placebo+Cisplatin+5-FU | Esophageal Carcinoma | First-line |
| KEYNOTE-590 | 3 | Active | Pembrolizumab+Cisplatin+5-FU/Placebo+Cisplatin+5-FU | Esophageal Carcinoma | First-line |
| NCT02954536 | 2 | Recruiting | Pembrolizumab +Trastuzumab+ Chemotherapy (Capecitabine/5-Fluorouracil+Cisplatin/Oxaliplatin) | Esophagogastric Carcinoma | First-line |
| NCT03342937 | 2 | Recruiting | Pembrolizumab + Oxaliplatin +Capecitabine | Esophagogastric Carcinoma | First-line |
| NCT03615326 | 3 | Recruiting | Pembrolizumab+Trastuzumab+Chemotherapy/Placebo+Trastuzumab+Chemotherapy (Capecitabine/5-Fluorouracil/S-1+Cisplatin/Oxaliplatin) | Gastroesophageal junction and gastric adenocarcinoma | First-line |
| Checkmate 648 | 3 | Recruiting | Nivolumab + Ipilimumab/Nivolumab + Cisplatin + Fluorouracil/Cisplatin + Fluorouracil | Esophageal Carcinoma | First-line |
| NCT03409848 | 3 | Recruiting | Nivolumab and Trastuzumab +Ipilimumab/FOLFOX | Esophagogastric Carcinoma | First-line |
| NCT03829969 | 3 | Recruiting | JS001 +paclitaxel +cisplatin/placebo +paclitaxel +cisplatin | Esophageal Squamous Cell Carcinoma | First-line |
| NCT03691090 | 3 | Recruiting | SHR-1210 + paclitaxel + cisplatin/placebo +paclitaxel +cisplatin | Esophageal squamous cell carcinoma | First-line |
| NCT03603756 | 2 | Recruiting | SHR-1210 + Apatinib+ Chemotherapy (irinotecan/paclitaxel+ nedaplatin) | Esophageal Squamous Cell Carcinoma | First-line |